Skip to main content

Advertisement

SpringerLink
Log in

Is Medication Overuse Drug Specific or Not? Data from a Review of Published Literature and from an Original Study on Italian MOH Patients

  • Migraine and Beyond (R Cowan, Section Editor)
  • Published:
Current Pain and Headache Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

The aim is twofold. First, to give an insight on the role exerted by different classes of drugs in favouring migraine chronification. Second, to explore the relationship between type and amount of overused medications and history of previous withdrawal treatment and of frequent relapses.

Recent Findings

All drug classes were found to favour migraine chronification. No data are available for the association with relapses into CM-MOH. Our clinical study shows that patients who underwent previous withdrawal treatments were more likely to be overusers of multiple drug classes and overuse higher amounts of symptomatic medications, particularly, indomethacin, eletriptan and tramadol. Frequent relapsers were more likely to be overusers of opioids or ergotamine and caffeine derivates or of multiple classes, particularly acetylsalicylic acid and ergotamine/caffeine derivates.

Summary

The joint results our review and clinical study do not seem to support the idea that MOH is drug-specific: rather, it points out that all drug classes may induce migraine chronification. Those drugs which are at higher risk of overuse are among those preferred by the “worst” patients, i.e. those who needed one or more withdrawal treatments for MOH. Our results reinforce the clinical impression that patients with CM and MOH, and particularly the most difficult to treat for their poor response to withdrawal treatments, are characterised by a particular drive towards the consumption of “whatever is likely to be perceived to provide some relief”, despite these drugs that are perceived as “more powerful”, are often indicated as second- or third-line medications.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. International Classification Committee of the International Headache Society (IHS). The international classification of headache disorders, 3rd ed. Cephalalgia. 2018;38:1–211.

    Google Scholar 

  2. •• Bigal ME, Serrano D, Buse D, Scher A, Stewart WF, Lipton RB. Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study. Headache. 2008;48(8):1157–68. This is one of the first and most important studies addressing the risk of chronification connected to the use of acute medications.

    Article  PubMed  Google Scholar 

  3. Raggi A, Schiavolin S, Leonardi M, Giovannetti AM, Bussone G, Curone M, et al. Chronic migraine with medication overuse: association between disability and quality of life measures, and impact of disease on patients’ lives. J Neurol Sci. 2015;348(1–2):60–6.

    Article  PubMed  Google Scholar 

  4. Andrasik F, Grazzi L, Usai S, Kass S, Bussone G. Disability in chronic migraine with medication overuse: treatment effects through 5 years. Cephalalgia. 2010;30:610–4.

    Article  CAS  PubMed  Google Scholar 

  5. Raggi A, Leonardi M, Giovannetti AM, Schiavolin S, Bussone G, Grazzi L, et al. A 14-month study of change in disability and mood state in patients with chronic migraine associated to medication overuse. Neurol Sci. 2013;34(Suppl 1):139–40.

    Article  Google Scholar 

  6. Bendtsen L, Munksgaard S, Tassorelli C, Nappi G, Katsarava Z, Lainez M, et al. Disability, anxiety and depression associated with medication-overuse headache can be considerably reduced by detoxification and prophylactic treatment. Results from a multicentre, multinational study (COMOESTAS project). Cephalalgia. 2014;34:426–33.

    Article  CAS  PubMed  Google Scholar 

  7. Lantéri-Minet M, Duru G, Mudge M, Cottrell S. Quality of life impairment, disability and economic burden associated with chronic daily headache, focusing on chronic migraine with or without medication overuse: a systematic review. Cephalalgia. 2011;31:837–50.

    Article  PubMed  Google Scholar 

  8. Raggi A, Giovannetti AM, Leonardi M, Schiavolin S, D’Amico D, Curone M, et al. Disability and mood state in patients with episodic and chronic migraine associated to medication overuse. Neurol Sci. 2012;33(Suppl 1):169–71.

    Article  Google Scholar 

  9. Bigal ME, Lipton RB. Concepts and mechanisms of migraine chronification. Headache. 2008;48(1):7–15.

    Article  PubMed  Google Scholar 

  10. Bigal ME, Lipton RB. Migraine chronification. Curr Neurol Neurosci Rep. 2011;11(2):139–48.

    Article  PubMed  Google Scholar 

  11. Natoli JL, Manack A, Dean B, Butler Q, Turkel CC, Stovner L, et al. Global prevalence of chronic migraine: a systematic review. Cephalalgia. 2010;30(5):599–609.

    Article  CAS  PubMed  Google Scholar 

  12. D’Andrea G, D’Amico D, Bussone G, Bolner A, Aguggia M, Saracco MG, et al. The role of tyrosine metabolism in the pathogenesis of chronic migraine. Cephalalgia. 2013;33:932–7.

    Article  PubMed  Google Scholar 

  13. Misra UK, Kalita J, Tripathi GM, Bhoi SK. Is β-endorphin related to migraine headache and its relief? Cephalalgia. 2013;33:316–22.

    Article  PubMed  Google Scholar 

  14. Cevoli S, Sancisi E, Grimaldi D, Pierangeli G, Zanigni S, Nicodemo M, et al. Family history for chronic headache and drug overuse as a risk factor for headache chronification. Headache. 2009;49:412–8.

    Article  PubMed  Google Scholar 

  15. Evers S, Jensen R. Treatment of medication overuse headache guideline of the EFNS headache panel. Eur J Neurol. 2011;18:1115–21.

    Article  CAS  PubMed  Google Scholar 

  16. Tassorelli C, Diener HC, Dodick DW, Silberstein SD, Lipton RB, Ashina M, et al. International Headache Society Clinical Trials Standing Committee. Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults. Cephalalgia. 2018;38(5):815–32.

    Article  PubMed  Google Scholar 

  17. • Katsarava Z, Muessig M, Dzagnidze A, Fritsche G, Diener HC, Limmroth V. Medication overuse headache: rates and predictors for relapse in a 4-year prospective study. Cephalalgia. 2005;25:12–5. This is the first study addressing long-term relapse rate and providing data on the "protective" effect of triptans on relapse rate into MOH.

    Article  CAS  PubMed  Google Scholar 

  18. • Katsarava Z, Limmroth V, Finke M, Diener HC, Fritsche G. Rates and predictors for relapse in medication overuse headache: a 1-year prospective study. Neurology. 2003;60:1682–3. This is one of the the first study addressing medium-term relapse rate and providing data on the "protective" effect of triptans on relapse rate into MOH.

    Article  CAS  PubMed  Google Scholar 

  19. Rossi P, Faroni JV, Nappi G. Medication overuse headache: predictors and rates of relapse in migraine patients with low medical needs. A 1-year prospective study. Cephalalgia. 2008;28:1196–200.

    Article  CAS  PubMed  Google Scholar 

  20. Biagianti B, Grazzi L, Usai S, Gambini O. Dependency-like behaviors and pain coping styles in subjects with chronic migraine and medication overuse: results from a 1-year follow-up study. BMC Neurol. 2014;14:181.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Cargnin S, Viana M, Ghiotto N, Bianchi M, Sances G, Tassorelli C, et al. Functional polymorphisms in COMT and SLC6A4 genes influence the prognosis of patients with medication overuse headache after withdrawal therapy. Eur J Neurol. 2014;21:989–95.

    Article  CAS  PubMed  Google Scholar 

  22. Raggi A, Giovannetti AM, Leonardi M, Sansone E, Schiavolin S, Curone M, et al. Predictors of 12-months relapse after withdrawal treatment in hospitalized patients with chronic migraine associated with medication overuse: a longitudinal observational study. Headache. 2017;57:60–70.

    Article  PubMed  Google Scholar 

  23. Raggi A, Grazzi L, Ayadi R, Leonardi M, Proietti A, Schiavolin S, et al. Clinical and psychosocial features of frequent relapsers (FR) among patients with chronic migraine and medication overuse. Neurol Sci. 2017;38(Suppl 1):169–71.

    Article  PubMed  Google Scholar 

  24. Raggi A, Leonardi M, Scaratti C, Sansone E, Grazzi L, D’Amico D. Gender and education inequalities in the cost of medication-overuse headache. Neurol Sci. 2018;39(Suppl 1):117–9.

    Article  PubMed  Google Scholar 

  25. D’Amico D, Grazzi L, Curone M, Leonardi M, Raggi A. Cost of medication overuse headache in Italian patients at the time-point of withdrawal: a retrospective study based on real data. Neurol Sci. 2017;38(Suppl 1):3–6.

    Article  PubMed  Google Scholar 

  26. D’Amico D, Mosconi P, Genco S, Usai S, Prudenzano AM, Grazzi L. Et al. The Migraine Disability Assessment (MIDAS) questionnaire: translation and reliability of the Italian version. Cephalalgia. 2001;21:947–52.

    Article  PubMed  Google Scholar 

  27. Federici S, Bracalenti M, Meloni F, Luciano JV. World Health Organization disability assessment schedule 2.0: an international systematic review. Disabil Rehabil. 2017;39:2347–80.

    Article  PubMed  Google Scholar 

  28. Scaratti C, Covelli V, Guastafierro E, Leonardi M, Grazzi L, Rizzoli PB, et al. A qualitative study on patients with chronic migraine with medication overuse headache: comparing frequent and non-frequent relapsers. Headache. 2018 ( E-Pub ahead of print. https://doi.org/10.1111/head.13385).

  29. •• Bigal ME, Lipton RB. Overuse of acute migraine medications and migraine chronification. Curr pain headache rep. 2009;13(4):301–7. This is one of the first and most important studies addressing the risk of chronification connected to the use of acute medications.

    Article  PubMed  Google Scholar 

  30. •• Lipton RB, Serrano D, Nicholson RA, Buse DC, Runken MC, Reed ML. Impact of NSAID and Triptan use on developing chronic migraine: results from the American Migraine Prevalence and Prevention (AMPP) study. Headache. 2013;53(10):1548–63. This is a population study that addressed the risk of chronification connected to the use of triptans.

    Article  PubMed  Google Scholar 

  31. Bigal ME, Lipton RB. Excessive opioid use and the development of chronic migraine. Pain. 2009;142(3):179–82.

    Article  CAS  PubMed  Google Scholar 

  32. Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF. AMPP advisory group. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68(5):343–9.

    Article  CAS  PubMed  Google Scholar 

  33. Biondi DM. Opioid resistance in chronic daily headache: a synthesis of ideas from the bench and bedside. Curr Pain Headache Rep. 2003;7(1):67–75.

    Article  PubMed  Google Scholar 

  34. Wilkinson SM, Becker WJ, Heine JA. Opiate use to control bowel motility may induce chronic daily headache in patients with migraine. Headache. 2001;41(3):303–9.

    Article  CAS  PubMed  Google Scholar 

  35. Rothrock JF. The case for opiate/opioid therapy in the management of headache. Headache. 2012;52(Suppl 1):35–7.

    Article  PubMed  Google Scholar 

  36. Sarchielli P, Granella F, Prudenzano MP, Pini LA, Guidetti V, Bono G, et al. Italian guidelines for primary headaches: 2012 revised version. J Headache Pain. 2012;13(Suppl 2):31–70.

    Article  PubMed Central  Google Scholar 

  37. Dodick DW. Review of comorbidities and risk factors for the development of migraine complications (infarct and chronic migraine). Cephalalgia. 2009;29(Suppl 3):7–14.

    PubMed  Google Scholar 

  38. Sandrini G, Cerbo R, Del Bene E, Ferrari A, Genco S, Grazioli I, et al. Efficacy of dosing and re-dosing of two oral fixed combinations of indomethacin, prochlorperazine and caffeine compared with oral sumatriptan in the acute treatment of multiple migraine attacks: a double-blind, double-dummy, randomized, parallel group, multicentre study. Int J Clin Pract. 2007;61(8):1256–69.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. • Scher AI1, Lipton RB, Stewart WF, Bigal M. Patterns of medication use by chronic and episodic headache sufferers in the general population: results from the frequent headache epidemiology study. Cephalalgia. 2010;30(3):321–8. This is one of the most important population studies investigating the pattern of consumption of acute medications among CDH sufferers.

    Article  CAS  PubMed  Google Scholar 

  40. Ferrari A, Savino G, Gallesi D, Pinetti D, Bertolini A, Sances G, et al. Effect of overuse of the antimigraine combination of indomethacin, prochlorperazine and caffeine (IPC) on the disposition of its components in chronic headache patients. Pharmacol Res. 2006;54(2):142–9.

    Article  CAS  PubMed  Google Scholar 

  41. Jonsson P, Jakobsson A, Hensing G, Linde M, Moore CD, Hedenrud T. Holding on to the indispensable medication--a grounded theory on medication use from the perspective of persons with medication overuse headache. J Headache Pain. 2013;14:43.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Nichols VP, Ellard DR, Griffiths FE, Kamal A, Underwood M, SJC T. CHESS team. The lived experience of chronic headache: a systematic review and synthesis of the qualitative literature. BMJ Open. 2017;7(12):e019929.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Engstrom M, Hagen K, Bjork MH, Stovner LJ, Gravdahl GB, Stjern M, et al. Sleep quality, arousal and pain thresholds in migraineurs: a blinded controlled polysomnographic study. J Headache Pain. 2013;14:1–12.

    Article  Google Scholar 

  44. Florencio LL, Giantomassi MC, Carvalho GF, Gonçalves MC, Dach F, Fernández-de-Las-Peñas C, et al. Generalized pressure pain hypersensitivity in the cervical muscles in women with migraine. Pain Med. 2015;16:1629–34.

    Article  PubMed  Google Scholar 

  45. Weissman-Fogel I, Sprecher E, Granovsky Y, Yarnitsky M. Repeated noxious stimulation of the skin enhances cutaneous pain perception of migraine patients in-between attacks: clinical evidence for continuous sub-threshold increase in membrane excitability of central trigeminovascular neurons. Pain. 2003;104:693–700.

    Article  PubMed  Google Scholar 

  46. Lipton RB, Bigal ME, Ashina S, Burstein R, Silberstein S, Reed ML, et al. Cutaneous allodynia in the migraine population. Ann Neurol. 2008;63:148–58.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Baykan B, Ekizoglu E, Karli N, Kocasoy-Orhan E, Zarifoglu M, Saip S, et al. Characterization of migraineurs having allodynia: results of a large population-based study. Clin J Pain. 2016;32:631–5.

    Article  PubMed  Google Scholar 

  48. Mathur VA, Moayedi M, Keaser ML, Khan SA, Hubbard CS, Goyal M, et al. High frequency migraine is associated with lower acute pain sensitivity and abnormal insula activity related to migraine pain intensity, attack frequency, and pain catastrophizing. Front Hum Neurosci. 2016;10:489.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Hubbard CS, Khan SA, Keaser ML, Mathur VA, Goyal M, Seminowicz DA. Altered brain structure and function correlate with disease severity and pain catastrophizing in migraine patients. eNeuro. 2014;1(1):e20.14.

    Article  PubMed  Google Scholar 

  50. Schwedt TJ, Alam A, Reed ML, Fanning KM, Munjal S, Buse DC, et al. Factors associated with acute medication overuse in people with migraine: results from the 2017 migraine in America symptoms and treatment (MAST) study. J Headache Pain. 2018;19(1):38.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Louter MA, Bosker JE, van Oosterhout WP, van Zwet EW, Zitman FG, Ferrari MD, et al. Cutaneous allodynia as a predictor of migraine chronification. Brain. 2013;136(Pt 11):3489–96.

    Article  PubMed  Google Scholar 

  52. Bigal ME, Lipton RB. What predicts the change from episodic to chronic migraine? Curr Opin Neurol. 2009;22(3):269–76.

    Article  PubMed  Google Scholar 

  53. Leonardi M, Raggi A, Bussone G, D’Amico D. Health-related quality of life, disability and severity of disease in patients with migraine attending to a specialty headache center. Headache. 2010;50:1576–86.

    Article  PubMed  Google Scholar 

  54. Raggi A, Grazzi L, Grignani E, Leonardi M, Sansone E, Scaratti C, et al. The use of MIDAS in patients with chronic migraine and medication-overuse headache: should we trust it? Neurol Sci. 2018;39(Suppl 1):125–7.

    Article  PubMed  Google Scholar 

  55. Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet. 2001;358(9294):1668–75.

    Article  CAS  PubMed  Google Scholar 

  56. Cameron C, Kelly S, Hsieh SC, Murphy M, Chen L, Kotb A, et al. Triptans in the acute treatment of migraine: a systematic review and network meta-analysis. Headache. 2015;55(Suppl 4):221–35.

    Article  PubMed  Google Scholar 

  57. Thorlund K, Mills EJ, Wu P, Ramos E, Chatterjee A, Druyts E, et al. Comparative efficacy of triptans for the abortive treatment of migraine: a multiple treatment comparison meta-analysis. Cephalalgia. 2014;34(4):258–67.

    Article  PubMed  Google Scholar 

  58. Ashaye T, Hounsome N, Carnes D, Taylor SJC, Homer K, Eldridge S, et al. COPERS Study Team (ISRCTN 24426731). Opioid prescribing for chronic musculoskeletal pain in UK primary care: results from a cohort analysis of the COPERS trial. BMJ Open. 2018;8(6):e019491.

    PubMed  PubMed Central  Google Scholar 

  59. Hakkarainen H, Gustafsson B, Stockman O. A comparative trail of ergotamine tartrate, acetyl salicylic acid and a dextropropoxyphene compound in acute migraine attacks. Headache. 1978;18(1):35–9.

    Article  CAS  PubMed  Google Scholar 

  60. Anneken K, Evers S, Husstedt IW. Efficacy of fixed combinations of acetylsalicyclic acid, acetaminophen and caffeine in the treatment of idiopathic headache: a review. Eur J Neurol. 2010;17(4):534–e25.

    Article  CAS  PubMed  Google Scholar 

  61. Bigal ME, Lipton RB. Excessive acute migraine medication use and migraine progression. Neurology. 2008;71(22):1821–8.

    Article  CAS  PubMed  Google Scholar 

  62. Lipton RB. Ergotamine tartrate and dihydroergotamine mesylate: safety profiles. Headache. 1997;37(Suppl 1):33–41.

    Google Scholar 

  63. Raggi A, Grignani E, Leonardi M, Andrasik F, Sansone E, Grazzi L, et al. Behavioral approaches for primary headaches: recent advances. Headache. 2018;58(6):913–25.

    Article  PubMed  Google Scholar 

  64. Andrasik F, Grazzi L, D’Amico D, Sansone E, Leonardi M, Raggi A, et al. Mindfulness and headache: a "new" old treatment, with new findings. Cephalalgia. 2016;36(12):1192–205.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Neuroalgology, Fondazione IRCCS Istituto Neurologico Carlo Besta, Via Celoria 11, 20133, Milan, Italy

    Licia Grazzi, Domenico D’Amico & Emanuela Sansone

  2. Neurology, Public Health and Disability Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Via Celoria 11, 20133, Milan, Italy

    Eleonora Grignani & Alberto Raggi

Authors
  1. Licia Grazzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eleonora Grignani
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Domenico D’Amico
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Emanuela Sansone
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Alberto Raggi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Licia Grazzi.

Ethics declarations

The protocol was approved by the Besta Institute Ethical Committee (protocol no. 379/2015).

Conflict of Interest

The authors declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Migraine and Beyond

Electronic Supplementary Material

ESM 1

(DOCX 22 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Grazzi, L., Grignani, E., D’Amico, D. et al. Is Medication Overuse Drug Specific or Not? Data from a Review of Published Literature and from an Original Study on Italian MOH Patients. Curr Pain Headache Rep 22, 71 (2018). https://doi.org/10.1007/s11916-018-0729-x

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11916-018-0729-x

Keywords

Search

Navigation